Clinical Trial: Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma

U.S., Dec. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07265947) titled 'Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma' on Nov. 19.

Brief Summary: A Phase 2A/B study of Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial Carcinoma

Study Start Date: Dec., 2025

Study Type: INTERVENTIONAL

Condition: Low Grade Upper Tract Urothelial Carcinoma

Intervention: DRUG: Dabogratinib (TYRA-300) 60mg

Self-administered 60mg dose Oral tablet(s) given daily

DRUG: Dabogratinib (TYRA-300) 80mg

Self-administered 80mg dose Oral tablet(s) given daily

DRUG: Dabogratinib (TYRA-300) TBD

To be determined: Self-administered Oral tablet(s) given dail...